Q-omics provides the consensus-scored METTL16 profile across patient tissues and cancer cell-line models. METTL16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, METTL16 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, METTL16 RNA expression shows 20,406 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where METTL16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL16 survival associations across molecular data types. METTL16 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL16 RNA expression–survival associations across cancer types. High METTL16 expression shows unfavorable associations in UVM, KICH, LUSC and LIHC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for METTL16 RNA expression.
This table summarizes METTL16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for METTL16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL16 shows lower tumor expression in KICH and BLCA and higher tumor expression in HNSC, COAD, LIHC and CHOL. The HNSC box plot shows higher METTL16 RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with METTL16 in patient tissues and cancer cell lines. In patient samples, METTL16 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
